An individualized left ventricular lead-targeting strategy improves long-term survival of cardiac resynchronization therapy patients and influences the benefit of the implantable cardioverter-defibrillator: a long-term follow-up of the TARGET study

    loading  Checking for direct PDF access through Ovid

Excerpt

The Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy (TARGET) study was a randomized controlled trial that enrolled patients eligible for cardiac resynchronization therapy (CRT) to assess the impact of prospectively targeting the left ventricular lead at the most delayed viable segment previously defined by speckle-tracking echocardiography.1 Compared with CRT treatment without echocardiographic guidance, the use of speckle-tracking echocardiography yielded significantly improved response and clinical status and lower rates of combined death and heart failure related hospitalization.1 In a longer follow-up (median of 39 months), an optimal left ventricular lead location at the site of latest mechanical activation was shown to associate with reduced all-cause mortality.

Related Topics

    loading  Loading Related Articles